Linda Watkins
Concepts (966)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuralgia | 41 | 2026 | 144 | 11.500 |
Why?
| | Hyperalgesia | 71 | 2026 | 131 | 11.380 |
Why?
| | Toll-Like Receptor 4 | 46 | 2023 | 276 | 8.040 |
Why?
| | Pain | 62 | 2026 | 777 | 7.570 |
Why?
| | Microglia | 55 | 2024 | 268 | 6.960 |
Why?
| | Rats, Sprague-Dawley | 241 | 2026 | 2525 | 6.720 |
Why?
| | Spinal Cord | 50 | 2023 | 380 | 5.850 |
Why?
| | Rats | 283 | 2026 | 5592 | 5.700 |
Why?
| | Morphine | 41 | 2020 | 168 | 5.470 |
Why?
| | Neuroglia | 39 | 2015 | 172 | 4.640 |
Why?
| | Neuroimmunomodulation | 35 | 2025 | 68 | 4.430 |
Why?
| | Interleukin-10 | 23 | 2024 | 309 | 3.850 |
Why?
| | Analgesics, Opioid | 38 | 2019 | 1131 | 3.780 |
Why?
| | Animals | 365 | 2026 | 38030 | 3.220 |
Why?
| | Chronic Pain | 10 | 2026 | 290 | 3.140 |
Why?
| | Cytokines | 53 | 2024 | 2061 | 3.110 |
Why?
| | Interleukin-1beta | 33 | 2023 | 395 | 2.890 |
Why?
| | Interleukin-1 | 51 | 2011 | 961 | 2.820 |
Why?
| | Spinal Cord Injuries | 9 | 2021 | 240 | 2.730 |
Why?
| | Stress, Psychological | 60 | 2020 | 1147 | 2.720 |
Why?
| | Inflammation | 51 | 2024 | 2877 | 2.500 |
Why?
| | Behavior, Animal | 55 | 2020 | 519 | 2.460 |
Why?
| | Sciatic Neuropathy | 13 | 2023 | 32 | 2.460 |
Why?
| | Lymphocyte Antigen 96 | 12 | 2019 | 24 | 2.400 |
Why?
| | Lipopolysaccharides | 52 | 2023 | 863 | 2.390 |
Why?
| | Signal Transduction | 42 | 2025 | 5221 | 2.320 |
Why?
| | Genetic Therapy | 16 | 2024 | 313 | 2.250 |
Why?
| | Injections, Spinal | 39 | 2018 | 120 | 2.220 |
Why?
| | Pain Threshold | 23 | 2019 | 73 | 2.220 |
Why?
| | Central Nervous System | 13 | 2018 | 281 | 2.150 |
Why?
| | Hippocampus | 51 | 2020 | 965 | 2.140 |
Why?
| | Stress, Physiological | 45 | 2017 | 453 | 2.000 |
Why?
| | Pain Measurement | 37 | 2024 | 552 | 2.000 |
Why?
| | Narcotic Antagonists | 20 | 2020 | 204 | 1.930 |
Why?
| | Corticosterone | 33 | 2019 | 244 | 1.930 |
Why?
| | Inflammasomes | 9 | 2023 | 146 | 1.930 |
Why?
| | Inflammation Mediators | 16 | 2020 | 508 | 1.790 |
Why?
| | Analgesia | 13 | 2015 | 105 | 1.770 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 5 | 2021 | 66 | 1.750 |
Why?
| | Naltrexone | 19 | 2023 | 117 | 1.720 |
Why?
| | Raphe Nuclei | 30 | 2014 | 110 | 1.710 |
Why?
| | Male | 286 | 2026 | 72035 | 1.680 |
Why?
| | Adenosine A2 Receptor Agonists | 4 | 2018 | 24 | 1.680 |
Why?
| | Disease Models, Animal | 46 | 2024 | 4556 | 1.600 |
Why?
| | HIV Envelope Protein gp120 | 12 | 2010 | 55 | 1.590 |
Why?
| | Vagus Nerve | 16 | 2001 | 91 | 1.520 |
Why?
| | Plasmids | 9 | 2024 | 379 | 1.470 |
Why?
| | Sciatic Nerve | 11 | 2024 | 59 | 1.450 |
Why?
| | Fear | 34 | 2020 | 366 | 1.450 |
Why?
| | Peripheral Nervous System Diseases | 10 | 2012 | 133 | 1.430 |
Why?
| | Naloxone | 16 | 2019 | 132 | 1.380 |
Why?
| | Prefrontal Cortex | 20 | 2018 | 328 | 1.360 |
Why?
| | HMGB1 Protein | 12 | 2019 | 51 | 1.350 |
Why?
| | Helplessness, Learned | 21 | 2012 | 67 | 1.310 |
Why?
| | Brain | 34 | 2024 | 2930 | 1.270 |
Why?
| | Immune System | 9 | 2026 | 179 | 1.250 |
Why?
| | Minocycline | 8 | 2017 | 22 | 1.240 |
Why?
| | Encephalitis | 10 | 2018 | 139 | 1.230 |
Why?
| | Receptors, Interleukin-1 | 17 | 2016 | 213 | 1.170 |
Why?
| | Neurons | 26 | 2022 | 1640 | 1.160 |
Why?
| | Electroshock | 61 | 2018 | 145 | 1.130 |
Why?
| | Astrocytes | 10 | 2019 | 222 | 1.130 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 11 | 2023 | 169 | 1.130 |
Why?
| | Glucocorticoids | 17 | 2019 | 533 | 1.110 |
Why?
| | Tumor Necrosis Factor-alpha | 27 | 2019 | 1217 | 1.100 |
Why?
| | Serotonin | 32 | 2020 | 293 | 1.090 |
Why?
| | Peripheral Nerve Injuries | 5 | 2023 | 37 | 1.080 |
Why?
| | Piperidines | 5 | 2018 | 217 | 1.070 |
Why?
| | Escape Reaction | 25 | 2014 | 56 | 1.070 |
Why?
| | Conditioning, Classical | 11 | 2020 | 120 | 1.060 |
Why?
| | Somatosensory Cortex | 3 | 2026 | 42 | 1.060 |
Why?
| | Pain Management | 8 | 2021 | 405 | 1.030 |
Why?
| | Toll-Like Receptor 2 | 7 | 2021 | 126 | 1.030 |
Why?
| | Nucleus Accumbens | 9 | 2019 | 132 | 1.030 |
Why?
| | Dependovirus | 2 | 2024 | 79 | 1.000 |
Why?
| | Central Nervous System Stimulants | 6 | 2019 | 182 | 0.980 |
Why?
| | Memory Disorders | 15 | 2020 | 193 | 0.960 |
Why?
| | Osteoarthritis | 2 | 2020 | 195 | 0.900 |
Why?
| | Dose-Response Relationship, Drug | 41 | 2023 | 2026 | 0.890 |
Why?
| | Conditioning, Operant | 13 | 2017 | 97 | 0.890 |
Why?
| | Acute Pain | 1 | 2026 | 54 | 0.880 |
Why?
| | Escherichia coli Infections | 15 | 2014 | 129 | 0.870 |
Why?
| | MicroRNAs | 3 | 2021 | 700 | 0.870 |
Why?
| | Low-Level Light Therapy | 1 | 2024 | 7 | 0.860 |
Why?
| | Dopamine | 8 | 2019 | 283 | 0.850 |
Why?
| | Circadian Rhythm | 8 | 2019 | 513 | 0.830 |
Why?
| | RNA, Messenger | 26 | 2017 | 2829 | 0.830 |
Why?
| | Ventral Tegmental Area | 4 | 2019 | 60 | 0.820 |
Why?
| | Glucuronides | 2 | 2014 | 18 | 0.820 |
Why?
| | Vagotomy | 15 | 2001 | 33 | 0.820 |
Why?
| | Alarmins | 5 | 2018 | 27 | 0.810 |
Why?
| | Fever | 11 | 2011 | 311 | 0.810 |
Why?
| | Posterior Horn Cells | 2 | 2019 | 10 | 0.800 |
Why?
| | Ganglia, Spinal | 6 | 2016 | 88 | 0.800 |
Why?
| | Psoriasis | 1 | 2024 | 112 | 0.790 |
Why?
| | Narcotics | 8 | 2014 | 55 | 0.780 |
Why?
| | Cocaine | 5 | 2023 | 160 | 0.780 |
Why?
| | Motor Activity | 21 | 2023 | 720 | 0.770 |
Why?
| | Physical Stimulation | 13 | 2014 | 68 | 0.760 |
Why?
| | Aging | 16 | 2021 | 1964 | 0.750 |
Why?
| | Morphine Derivatives | 2 | 2014 | 19 | 0.750 |
Why?
| | Analysis of Variance | 27 | 2018 | 1304 | 0.740 |
Why?
| | Pyridines | 7 | 2017 | 605 | 0.730 |
Why?
| | Chemokines, CX3C | 4 | 2005 | 10 | 0.730 |
Why?
| | Toll-Like Receptors | 6 | 2017 | 194 | 0.720 |
Why?
| | Drug Delivery Systems | 5 | 2024 | 379 | 0.700 |
Why?
| | Rats, Inbred F344 | 19 | 2018 | 268 | 0.700 |
Why?
| | Drug Tolerance | 6 | 2017 | 100 | 0.700 |
Why?
| | Methamphetamine | 3 | 2019 | 68 | 0.690 |
Why?
| | Time Factors | 42 | 2019 | 7155 | 0.680 |
Why?
| | Sciatica | 6 | 2012 | 7 | 0.680 |
Why?
| | Phenethylamines | 2 | 2018 | 19 | 0.650 |
Why?
| | Anti-Inflammatory Agents | 4 | 2018 | 474 | 0.650 |
Why?
| | Migraine Disorders | 3 | 2017 | 112 | 0.640 |
Why?
| | Amygdala | 10 | 2017 | 198 | 0.640 |
Why?
| | Interleukin-6 | 15 | 2014 | 780 | 0.630 |
Why?
| | Nociceptors | 8 | 2006 | 41 | 0.630 |
Why?
| | Nicotinic Agonists | 2 | 2012 | 136 | 0.620 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 14 | 2012 | 253 | 0.620 |
Why?
| | Arthralgia | 1 | 2020 | 61 | 0.620 |
Why?
| | Anxiety | 15 | 2020 | 1104 | 0.620 |
Why?
| | Laparotomy | 5 | 2020 | 112 | 0.600 |
Why?
| | Gene Expression Regulation | 19 | 2019 | 2603 | 0.590 |
Why?
| | Substance-Related Disorders | 4 | 2024 | 1054 | 0.590 |
Why?
| | Defecation | 1 | 2019 | 18 | 0.580 |
Why?
| | Receptors, Nicotinic | 2 | 2012 | 321 | 0.580 |
Why?
| | Chronobiology Disorders | 1 | 2018 | 16 | 0.580 |
Why?
| | Adenosine | 2 | 2018 | 254 | 0.570 |
Why?
| | Reactive Oxygen Species | 2 | 2016 | 621 | 0.570 |
Why?
| | Neural Pathways | 13 | 2026 | 311 | 0.560 |
Why?
| | Spinal Cord Dorsal Horn | 3 | 2019 | 5 | 0.560 |
Why?
| | Synapses | 1 | 2022 | 439 | 0.560 |
Why?
| | Multiple Sclerosis | 4 | 2021 | 484 | 0.560 |
Why?
| | Sex Characteristics | 5 | 2018 | 789 | 0.530 |
Why?
| | Humans | 95 | 2026 | 144261 | 0.530 |
Why?
| | Neurons, Afferent | 4 | 2007 | 102 | 0.530 |
Why?
| | Neuroprotective Agents | 3 | 2015 | 143 | 0.520 |
Why?
| | Immunity, Innate | 14 | 2019 | 846 | 0.520 |
Why?
| | Trigeminal Caudal Nucleus | 1 | 2017 | 1 | 0.520 |
Why?
| | Contusions | 1 | 2017 | 25 | 0.520 |
Why?
| | Ethanol | 5 | 2014 | 625 | 0.520 |
Why?
| | Proto-Oncogene Proteins c-fos | 14 | 2018 | 196 | 0.510 |
Why?
| | Facial Nerve Injuries | 1 | 2016 | 3 | 0.510 |
Why?
| | Macrophages | 11 | 2017 | 1510 | 0.510 |
Why?
| | Reactive Nitrogen Species | 1 | 2016 | 16 | 0.500 |
Why?
| | Spinal Injuries | 1 | 2017 | 58 | 0.500 |
Why?
| | Membrane Proteins | 5 | 2010 | 1165 | 0.500 |
Why?
| | Facial Nerve | 1 | 2016 | 39 | 0.500 |
Why?
| | Exercise Movement Techniques | 1 | 2016 | 7 | 0.500 |
Why?
| | Reward | 8 | 2015 | 245 | 0.480 |
Why?
| | Cells, Cultured | 17 | 2020 | 4146 | 0.480 |
Why?
| | Catheters, Indwelling | 3 | 2012 | 96 | 0.480 |
Why?
| | NADPH Oxidases | 1 | 2016 | 124 | 0.480 |
Why?
| | Reaction Time | 17 | 2012 | 438 | 0.480 |
Why?
| | DNA | 6 | 2024 | 1460 | 0.480 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 2 | 2014 | 125 | 0.470 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2018 | 233 | 0.460 |
Why?
| | Catheterization | 6 | 2007 | 183 | 0.460 |
Why?
| | Xanthines | 2 | 2014 | 22 | 0.460 |
Why?
| | Memory | 10 | 2018 | 294 | 0.460 |
Why?
| | Hindlimb | 3 | 2013 | 131 | 0.460 |
Why?
| | Excitatory Amino Acid Transporter 2 | 2 | 2016 | 15 | 0.450 |
Why?
| | Dorsal Raphe Nucleus | 4 | 2020 | 31 | 0.440 |
Why?
| | Microinjections | 19 | 2018 | 92 | 0.440 |
Why?
| | Paralysis | 2 | 2015 | 67 | 0.440 |
Why?
| | Liver | 6 | 2019 | 1884 | 0.440 |
Why?
| | Endotoxins | 5 | 2012 | 220 | 0.440 |
Why?
| | Xenobiotics | 1 | 2015 | 32 | 0.430 |
Why?
| | Resilience, Psychological | 3 | 2018 | 135 | 0.420 |
Why?
| | Gliosis | 4 | 2013 | 29 | 0.420 |
Why?
| | T-Lymphocytes | 2 | 2021 | 1982 | 0.410 |
Why?
| | Chronic Disease | 11 | 2017 | 1812 | 0.410 |
Why?
| | Fatigue | 1 | 2016 | 361 | 0.400 |
Why?
| | Neuropharmacology | 1 | 2013 | 4 | 0.400 |
Why?
| | Disease | 4 | 1999 | 98 | 0.390 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 144 | 0.390 |
Why?
| | Glucuronic Acid | 1 | 2013 | 25 | 0.390 |
Why?
| | Corticotropin-Releasing Hormone | 7 | 2005 | 72 | 0.390 |
Why?
| | Hot Temperature | 10 | 2009 | 405 | 0.390 |
Why?
| | Quinuclidines | 1 | 2012 | 11 | 0.380 |
Why?
| | Allergy and Immunology | 1 | 2013 | 42 | 0.380 |
Why?
| | HSP90 Heat-Shock Proteins | 2 | 2010 | 47 | 0.380 |
Why?
| | Myeloid Differentiation Factor 88 | 5 | 2014 | 114 | 0.370 |
Why?
| | Injections, Intraperitoneal | 16 | 2009 | 116 | 0.370 |
Why?
| | Models, Animal | 1 | 2014 | 392 | 0.360 |
Why?
| | Estradiol | 2 | 2014 | 533 | 0.360 |
Why?
| | Arthritis, Rheumatoid | 1 | 2021 | 1168 | 0.360 |
Why?
| | Facial Pain | 1 | 2012 | 12 | 0.360 |
Why?
| | Exploratory Behavior | 7 | 2018 | 86 | 0.360 |
Why?
| | Thiophenes | 1 | 2012 | 128 | 0.360 |
Why?
| | Protein Kinase C | 1 | 2013 | 252 | 0.360 |
Why?
| | Hyperesthesia | 3 | 2007 | 6 | 0.360 |
Why?
| | Mice | 24 | 2024 | 18329 | 0.350 |
Why?
| | Neuralgia, Postherpetic | 1 | 2012 | 39 | 0.350 |
Why?
| | NF-kappa B | 8 | 2019 | 661 | 0.350 |
Why?
| | Complement System Proteins | 2 | 2005 | 316 | 0.340 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2011 | 51 | 0.340 |
Why?
| | Brain-Derived Neurotrophic Factor | 6 | 2009 | 148 | 0.340 |
Why?
| | CD11b Antigen | 6 | 2010 | 60 | 0.340 |
Why?
| | Animals, Newborn | 14 | 2019 | 901 | 0.330 |
Why?
| | Female | 36 | 2026 | 77976 | 0.330 |
Why?
| | Avoidance Learning | 5 | 2018 | 64 | 0.330 |
Why?
| | Drug-Seeking Behavior | 2 | 2023 | 22 | 0.320 |
Why?
| | Ceftriaxone | 1 | 2010 | 21 | 0.320 |
Why?
| | Diet, High-Fat | 3 | 2017 | 261 | 0.320 |
Why?
| | Pyrazoles | 7 | 2017 | 509 | 0.320 |
Why?
| | Chemokines | 3 | 2021 | 218 | 0.310 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2010 | 43 | 0.310 |
Why?
| | Indolizines | 6 | 2017 | 13 | 0.310 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 11 | 2012 | 981 | 0.310 |
Why?
| | Receptor, Adenosine A2A | 1 | 2009 | 23 | 0.310 |
Why?
| | Morphinans | 3 | 2015 | 8 | 0.300 |
Why?
| | Genetic Vectors | 4 | 2024 | 337 | 0.300 |
Why?
| | Up-Regulation | 4 | 2013 | 851 | 0.300 |
Why?
| | Self Administration | 5 | 2023 | 124 | 0.300 |
Why?
| | Constriction, Pathologic | 4 | 2016 | 248 | 0.300 |
Why?
| | Receptors, Opioid, mu | 6 | 2020 | 68 | 0.300 |
Why?
| | Respiratory Insufficiency | 2 | 2014 | 326 | 0.300 |
Why?
| | Formaldehyde | 6 | 2013 | 66 | 0.290 |
Why?
| | Meninges | 2 | 2006 | 49 | 0.290 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2012 | 850 | 0.290 |
Why?
| | Sialoglycoproteins | 8 | 2004 | 158 | 0.290 |
Why?
| | Cell Line | 13 | 2019 | 2879 | 0.290 |
Why?
| | Neurotransmitter Agents | 2 | 2006 | 82 | 0.290 |
Why?
| | Behavior | 3 | 2006 | 91 | 0.290 |
Why?
| | Mice, Inbred BALB C | 7 | 2014 | 1253 | 0.280 |
Why?
| | Functional Laterality | 7 | 2016 | 241 | 0.280 |
Why?
| | Injections, Subcutaneous | 9 | 2012 | 164 | 0.280 |
Why?
| | Receptors, Tumor Necrosis Factor | 3 | 2004 | 163 | 0.270 |
Why?
| | HEK293 Cells | 6 | 2024 | 744 | 0.270 |
Why?
| | Endothelial Cells | 1 | 2014 | 869 | 0.270 |
Why?
| | Glutamic Acid | 1 | 2010 | 251 | 0.270 |
Why?
| | Face | 1 | 2009 | 173 | 0.270 |
Why?
| | Wakefulness | 1 | 2009 | 169 | 0.270 |
Why?
| | Cerebral Cortex | 4 | 2018 | 464 | 0.270 |
Why?
| | Parkinson Disease | 1 | 2014 | 600 | 0.270 |
Why?
| | Receptors, Immunologic | 3 | 2019 | 206 | 0.270 |
Why?
| | Receptors, Opioid | 3 | 2011 | 23 | 0.270 |
Why?
| | Microdialysis | 13 | 2012 | 53 | 0.270 |
Why?
| | Transgenes | 2 | 2024 | 189 | 0.270 |
Why?
| | Molecular Dynamics Simulation | 3 | 2019 | 258 | 0.270 |
Why?
| | Substance Withdrawal Syndrome | 5 | 2011 | 186 | 0.260 |
Why?
| | Drug Design | 2 | 2010 | 173 | 0.260 |
Why?
| | Receptors, Complement | 2 | 2005 | 125 | 0.260 |
Why?
| | Biomedical Research | 2 | 2013 | 709 | 0.260 |
Why?
| | Clozapine | 2 | 2018 | 20 | 0.260 |
Why?
| | Cues | 8 | 2013 | 326 | 0.260 |
Why?
| | Constriction | 3 | 2023 | 47 | 0.260 |
Why?
| | Hypothalamus | 5 | 2008 | 153 | 0.260 |
Why?
| | Alkaline Phosphatase | 3 | 2014 | 143 | 0.260 |
Why?
| | Crotalid Venoms | 2 | 2004 | 32 | 0.260 |
Why?
| | Locomotion | 2 | 2018 | 105 | 0.260 |
Why?
| | Drug Administration Schedule | 7 | 2019 | 778 | 0.260 |
Why?
| | Phospholipases A | 2 | 2004 | 98 | 0.250 |
Why?
| | Nitric Oxide | 7 | 2019 | 897 | 0.250 |
Why?
| | Chemokine CX3CL1 | 5 | 2008 | 25 | 0.250 |
Why?
| | Mycobacterium | 2 | 2018 | 116 | 0.250 |
Why?
| | Immunocompetence | 1 | 2006 | 47 | 0.250 |
Why?
| | Nerve Tissue Proteins | 5 | 2011 | 592 | 0.240 |
Why?
| | Immunohistochemistry | 17 | 2010 | 1715 | 0.240 |
Why?
| | Transfection | 3 | 2018 | 938 | 0.240 |
Why?
| | Cognition | 6 | 2018 | 1258 | 0.240 |
Why?
| | Dinoprostone | 4 | 2014 | 178 | 0.240 |
Why?
| | Limbic System | 3 | 2019 | 55 | 0.240 |
Why?
| | Citrates | 6 | 2006 | 41 | 0.240 |
Why?
| | Corpus Striatum | 3 | 2018 | 179 | 0.240 |
Why?
| | Ketamine | 3 | 2018 | 132 | 0.230 |
Why?
| | Cisterna Magna | 4 | 2013 | 8 | 0.230 |
Why?
| | Hypothalamo-Hypophyseal System | 5 | 2012 | 198 | 0.230 |
Why?
| | Neuronal Plasticity | 3 | 2022 | 309 | 0.230 |
Why?
| | Freezing Reaction, Cataleptic | 4 | 2013 | 27 | 0.230 |
Why?
| | Extinction, Psychological | 5 | 2023 | 92 | 0.230 |
Why?
| | Adaptation, Psychological | 2 | 2010 | 706 | 0.230 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2006 | 177 | 0.230 |
Why?
| | Paclitaxel | 1 | 2006 | 255 | 0.230 |
Why?
| | Bacterial Infections | 4 | 2009 | 246 | 0.230 |
Why?
| | Oxycodone | 3 | 2019 | 53 | 0.230 |
Why?
| | DNA-Binding Proteins | 3 | 2023 | 1497 | 0.220 |
Why?
| | Arousal | 6 | 2002 | 157 | 0.220 |
Why?
| | Protein Binding | 9 | 2018 | 2270 | 0.220 |
Why?
| | Aminoquinolines | 1 | 2024 | 18 | 0.220 |
Why?
| | Spinal Nerve Roots | 3 | 2012 | 29 | 0.220 |
Why?
| | Analgesics | 5 | 2020 | 228 | 0.220 |
Why?
| | Antibodies | 6 | 2018 | 401 | 0.220 |
Why?
| | Cyclooxygenase 2 | 4 | 2019 | 165 | 0.220 |
Why?
| | Models, Immunological | 1 | 2005 | 100 | 0.210 |
Why?
| | Infrared Rays | 1 | 2024 | 27 | 0.210 |
Why?
| | Nitric Oxide Synthase | 2 | 2004 | 235 | 0.210 |
Why?
| | Ligation | 3 | 2013 | 92 | 0.210 |
Why?
| | Administration, Cutaneous | 1 | 2024 | 125 | 0.210 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 338 | 0.210 |
Why?
| | Brain Mapping | 8 | 2018 | 536 | 0.210 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 4 | 2008 | 81 | 0.210 |
Why?
| | Injections, Intraventricular | 13 | 2015 | 56 | 0.210 |
Why?
| | Vesiculovirus | 1 | 2024 | 17 | 0.210 |
Why?
| | Models, Neurological | 2 | 2003 | 254 | 0.210 |
Why?
| | Central Nervous System Agents | 1 | 2003 | 7 | 0.210 |
Why?
| | Body Fluids | 1 | 2004 | 70 | 0.200 |
Why?
| | Cholecystokinin | 4 | 2000 | 15 | 0.200 |
Why?
| | Gap Junctions | 1 | 2004 | 67 | 0.200 |
Why?
| | Glial Fibrillary Acidic Protein | 8 | 2015 | 123 | 0.200 |
Why?
| | Transduction, Genetic | 1 | 2024 | 133 | 0.200 |
Why?
| | Carrier Proteins | 5 | 2015 | 736 | 0.200 |
Why?
| | Norepinephrine | 5 | 2005 | 196 | 0.200 |
Why?
| | Lumbosacral Region | 4 | 2013 | 59 | 0.200 |
Why?
| | Neural Inhibition | 2 | 2010 | 178 | 0.200 |
Why?
| | Central Nervous System Diseases | 2 | 2017 | 74 | 0.200 |
Why?
| | Antigens, CD | 4 | 2017 | 555 | 0.190 |
Why?
| | Animals, Genetically Modified | 1 | 2024 | 250 | 0.190 |
Why?
| | Mice, Knockout | 5 | 2021 | 3119 | 0.190 |
Why?
| | Adrenalectomy | 10 | 2014 | 71 | 0.190 |
Why?
| | Mifepristone | 6 | 2019 | 64 | 0.190 |
Why?
| | Enzyme Inhibitors | 6 | 2007 | 824 | 0.190 |
Why?
| | Freund's Adjuvant | 2 | 2013 | 18 | 0.190 |
Why?
| | Pituitary Gland | 6 | 2004 | 148 | 0.190 |
Why?
| | Receptors, Glucocorticoid | 5 | 2016 | 138 | 0.190 |
Why?
| | Learning | 7 | 2018 | 449 | 0.190 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2015 | 209 | 0.190 |
Why?
| | Opioid-Related Disorders | 5 | 2017 | 576 | 0.190 |
Why?
| | Illness Behavior | 2 | 2014 | 9 | 0.180 |
Why?
| | Brain Chemistry | 3 | 2004 | 116 | 0.180 |
Why?
| | Gene Expression | 8 | 2020 | 1487 | 0.180 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 2 | 2021 | 53 | 0.180 |
Why?
| | Fibroblast Growth Factor 2 | 3 | 2007 | 92 | 0.180 |
Why?
| | Random Allocation | 6 | 2016 | 363 | 0.180 |
Why?
| | Synaptic Transmission | 4 | 2010 | 290 | 0.180 |
Why?
| | Caspase 1 | 3 | 2020 | 148 | 0.180 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2016 | 266 | 0.180 |
Why?
| | Cognitive Dysfunction | 2 | 2018 | 451 | 0.180 |
Why?
| | Spleen | 7 | 2014 | 508 | 0.180 |
Why?
| | Social Behavior | 8 | 2018 | 288 | 0.180 |
Why?
| | Cocaine-Related Disorders | 1 | 2023 | 130 | 0.180 |
Why?
| | Psychoneuroimmunology | 3 | 2002 | 9 | 0.180 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 431 | 0.170 |
Why?
| | Immunity, Cellular | 2 | 2002 | 272 | 0.170 |
Why?
| | Affect | 3 | 2018 | 318 | 0.170 |
Why?
| | GABA Antagonists | 4 | 2010 | 34 | 0.170 |
Why?
| | Indoles | 4 | 2013 | 501 | 0.170 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 2 | 2012 | 93 | 0.170 |
Why?
| | Tail | 11 | 2007 | 29 | 0.170 |
Why?
| | Central Nervous System Depressants | 2 | 2014 | 83 | 0.170 |
Why?
| | Zymosan | 4 | 2005 | 39 | 0.170 |
Why?
| | 8-Hydroxy-2-(di-n-propylamino)tetralin | 4 | 2009 | 9 | 0.160 |
Why?
| | Receptors, HIV | 3 | 2004 | 23 | 0.160 |
Why?
| | Body Temperature | 5 | 2002 | 228 | 0.160 |
Why?
| | Cell Communication | 3 | 2009 | 324 | 0.160 |
Why?
| | Touch | 3 | 2013 | 39 | 0.160 |
Why?
| | Neurogenesis | 1 | 2022 | 156 | 0.160 |
Why?
| | Fentanyl | 2 | 2019 | 126 | 0.160 |
Why?
| | Dexamethasone | 5 | 2012 | 370 | 0.160 |
Why?
| | Drug Interactions | 6 | 2008 | 397 | 0.160 |
Why?
| | Receptors, Cytokine | 3 | 2004 | 36 | 0.160 |
Why?
| | Models, Molecular | 5 | 2012 | 1618 | 0.160 |
Why?
| | Thoracic Vertebrae | 2 | 2019 | 79 | 0.160 |
Why?
| | Convulsants | 4 | 1998 | 8 | 0.160 |
Why?
| | Specific Pathogen-Free Organisms | 5 | 2004 | 58 | 0.160 |
Why?
| | AIDS Dementia Complex | 1 | 2000 | 52 | 0.160 |
Why?
| | Drug Synergism | 4 | 2015 | 357 | 0.160 |
Why?
| | Dogs | 2 | 2020 | 437 | 0.160 |
Why?
| | Carbolines | 4 | 1998 | 35 | 0.160 |
Why?
| | Lithium Chloride | 3 | 1994 | 12 | 0.150 |
Why?
| | Skin | 1 | 2024 | 754 | 0.150 |
Why?
| | Lovastatin | 1 | 2019 | 37 | 0.150 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 4 | 2004 | 28 | 0.150 |
Why?
| | Hemocyanins | 8 | 2003 | 61 | 0.150 |
Why?
| | Antibody Formation | 6 | 2002 | 294 | 0.150 |
Why?
| | Microfilament Proteins | 3 | 2016 | 135 | 0.150 |
Why?
| | Thalamus | 2 | 2018 | 125 | 0.150 |
Why?
| | Immunization | 4 | 2018 | 374 | 0.150 |
Why?
| | CLOCK Proteins | 1 | 2018 | 9 | 0.150 |
Why?
| | Tumor Necrosis Factor Decoy Receptors | 3 | 2004 | 8 | 0.150 |
Why?
| | Purinergic P1 Receptor Agonists | 1 | 2018 | 7 | 0.150 |
Why?
| | Diaphragm | 5 | 2001 | 49 | 0.150 |
Why?
| | Pituitary-Adrenal System | 5 | 2004 | 165 | 0.140 |
Why?
| | Receptors, Purinergic P1 | 1 | 2018 | 30 | 0.140 |
Why?
| | Motor Disorders | 1 | 2018 | 17 | 0.140 |
Why?
| | Calcium-Binding Proteins | 3 | 2016 | 219 | 0.140 |
Why?
| | Medulla Oblongata | 2 | 2014 | 37 | 0.140 |
Why?
| | Restraint, Physical | 11 | 2007 | 75 | 0.140 |
Why?
| | Receptor, Serotonin, 5-HT1A | 2 | 2011 | 36 | 0.140 |
Why?
| | Recombinant Proteins | 8 | 2005 | 1367 | 0.140 |
Why?
| | Designer Drugs | 1 | 2018 | 6 | 0.140 |
Why?
| | Maze Learning | 2 | 2016 | 103 | 0.140 |
Why?
| | Mice, Inbred C57BL | 4 | 2021 | 5988 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 336 | 0.140 |
Why?
| | Septal Nuclei | 2 | 2011 | 23 | 0.140 |
Why?
| | Molecular Docking Simulation | 2 | 2018 | 123 | 0.140 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2018 | 52 | 0.140 |
Why?
| | Abdomen | 1 | 1999 | 141 | 0.140 |
Why?
| | Bacterial Vaccines | 1 | 2018 | 63 | 0.140 |
Why?
| | Body Weight | 4 | 2018 | 976 | 0.140 |
Why?
| | Transcortin | 4 | 1999 | 14 | 0.130 |
Why?
| | Probiotics | 1 | 2018 | 61 | 0.130 |
Why?
| | Cyclooxygenase 1 | 2 | 2008 | 26 | 0.130 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 427 | 0.130 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2018 | 107 | 0.130 |
Why?
| | Receptors, Purinergic P2X7 | 1 | 2017 | 12 | 0.130 |
Why?
| | Muscimol | 7 | 2011 | 23 | 0.130 |
Why?
| | Methadone | 2 | 2010 | 110 | 0.130 |
Why?
| | Brain Injuries | 2 | 2013 | 506 | 0.130 |
Why?
| | Amphetamine | 3 | 2010 | 38 | 0.130 |
Why?
| | Nitrites | 2 | 2016 | 89 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 459 | 0.130 |
Why?
| | Acoustic Stimulation | 5 | 2011 | 333 | 0.130 |
Why?
| | Biomarkers | 5 | 2012 | 4254 | 0.130 |
Why?
| | Taste | 3 | 2008 | 239 | 0.130 |
Why?
| | Facial Nucleus | 1 | 2016 | 1 | 0.130 |
Why?
| | Rats, Inbred Strains | 7 | 2017 | 321 | 0.130 |
Why?
| | Macrophage Activation | 1 | 2018 | 193 | 0.130 |
Why?
| | Dura Mater | 1 | 2017 | 35 | 0.130 |
Why?
| | Receptors, Purinergic P2X5 | 1 | 2016 | 4 | 0.130 |
Why?
| | Activating Transcription Factor 3 | 1 | 2016 | 5 | 0.130 |
Why?
| | Habenula | 1 | 2016 | 13 | 0.120 |
Why?
| | Toll-Like Receptor 5 | 1 | 2016 | 18 | 0.120 |
Why?
| | p21-Activated Kinases | 1 | 2016 | 14 | 0.120 |
Why?
| | Spatial Memory | 1 | 2016 | 28 | 0.120 |
Why?
| | Down-Regulation | 2 | 2017 | 627 | 0.120 |
Why?
| | CX3C Chemokine Receptor 1 | 3 | 2004 | 19 | 0.120 |
Why?
| | Radiculopathy | 2 | 2014 | 36 | 0.120 |
Why?
| | Guanidines | 3 | 2003 | 41 | 0.120 |
Why?
| | Models, Biological | 3 | 2017 | 1820 | 0.120 |
Why?
| | Brain Ischemia | 2 | 2018 | 358 | 0.120 |
Why?
| | Neurogenic Inflammation | 1 | 2016 | 2 | 0.120 |
Why?
| | Arrhythmias, Cardiac | 2 | 2018 | 360 | 0.120 |
Why?
| | Hydrazones | 3 | 2003 | 26 | 0.120 |
Why?
| | Cell Count | 9 | 2009 | 320 | 0.120 |
Why?
| | Analgesics, Non-Narcotic | 1 | 1997 | 123 | 0.120 |
Why?
| | Flumazenil | 1 | 1995 | 8 | 0.120 |
Why?
| | Anilides | 3 | 2003 | 84 | 0.120 |
Why?
| | Nociception | 2 | 2015 | 17 | 0.120 |
Why?
| | Life Expectancy | 1 | 2016 | 72 | 0.120 |
Why?
| | Physical Conditioning, Animal | 3 | 2014 | 243 | 0.110 |
Why?
| | Isomerism | 2 | 2018 | 57 | 0.110 |
Why?
| | Autoimmunity | 1 | 2021 | 924 | 0.110 |
Why?
| | Reflex, Abnormal | 1 | 2014 | 8 | 0.110 |
Why?
| | Excitatory Amino Acids | 1 | 1994 | 7 | 0.110 |
Why?
| | NG-Nitroarginine Methyl Ester | 2 | 2005 | 49 | 0.110 |
Why?
| | Antibodies, Neutralizing | 1 | 2018 | 340 | 0.110 |
Why?
| | Picrotoxin | 5 | 2018 | 12 | 0.110 |
Why?
| | Polyethylene Glycols | 2 | 2010 | 649 | 0.110 |
Why?
| | Mice, Inbred C3H | 1 | 2015 | 251 | 0.110 |
Why?
| | Drug Administration Routes | 2 | 2012 | 42 | 0.110 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2015 | 59 | 0.110 |
Why?
| | Body Temperature Regulation | 2 | 2009 | 107 | 0.110 |
Why?
| | Neuropeptides | 1 | 1994 | 77 | 0.110 |
Why?
| | Morphine Dependence | 2 | 2011 | 3 | 0.100 |
Why?
| | Memory, Long-Term | 3 | 2020 | 12 | 0.100 |
Why?
| | Circadian Clocks | 1 | 2014 | 59 | 0.100 |
Why?
| | Receptors, GABA-A | 1 | 1995 | 138 | 0.100 |
Why?
| | Thiazolidinediones | 1 | 2015 | 138 | 0.100 |
Why?
| | PPAR gamma | 1 | 2015 | 176 | 0.100 |
Why?
| | Host-Pathogen Interactions | 3 | 2012 | 371 | 0.100 |
Why?
| | Immunosuppressive Agents | 2 | 2013 | 846 | 0.100 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2014 | 73 | 0.100 |
Why?
| | Brain Stem | 2 | 2010 | 95 | 0.100 |
Why?
| | Nervous System | 1 | 1994 | 70 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 573 | 0.100 |
Why?
| | Phosphorylation | 3 | 2012 | 1732 | 0.100 |
Why?
| | Glucose | 1 | 2019 | 1046 | 0.100 |
Why?
| | Cell Death | 1 | 2015 | 383 | 0.100 |
Why?
| | B-Lymphocytes | 2 | 2012 | 876 | 0.100 |
Why?
| | Running | 2 | 2017 | 228 | 0.100 |
Why?
| | Escherichia coli | 5 | 2016 | 852 | 0.100 |
Why?
| | Pentamidine | 1 | 2012 | 3 | 0.100 |
Why?
| | Interleukins | 2 | 2006 | 248 | 0.100 |
Why?
| | Swimming | 1 | 2013 | 50 | 0.100 |
Why?
| | Recovery of Function | 1 | 2017 | 706 | 0.090 |
Why?
| | Heroin | 1 | 2013 | 29 | 0.090 |
Why?
| | Interpersonal Relations | 1 | 2016 | 399 | 0.090 |
Why?
| | Viral Matrix Proteins | 1 | 2012 | 29 | 0.090 |
Why?
| | Rats, Wistar | 4 | 2016 | 451 | 0.090 |
Why?
| | Rifampin | 1 | 2013 | 82 | 0.090 |
Why?
| | Blood-Brain Barrier | 2 | 2009 | 155 | 0.090 |
Why?
| | Serotonin Receptor Agonists | 4 | 2013 | 27 | 0.090 |
Why?
| | Adrenocorticotropic Hormone | 6 | 2004 | 147 | 0.090 |
Why?
| | Oncogene Proteins v-fos | 4 | 2015 | 11 | 0.090 |
Why?
| | Receptors, Cholecystokinin | 1 | 1992 | 9 | 0.090 |
Why?
| | Organ Culture Techniques | 2 | 2010 | 154 | 0.090 |
Why?
| | Lipopeptides | 1 | 2012 | 16 | 0.090 |
Why?
| | Somatostatin | 1 | 1992 | 51 | 0.090 |
Why?
| | Cytoskeletal Proteins | 2 | 2010 | 156 | 0.090 |
Why?
| | Cerebral Ventricles | 1 | 1992 | 54 | 0.090 |
Why?
| | Structure-Activity Relationship | 3 | 2019 | 567 | 0.090 |
Why?
| | DNA, Complementary | 2 | 2010 | 276 | 0.090 |
Why?
| | Association Learning | 4 | 2007 | 71 | 0.090 |
Why?
| | Cell Line, Transformed | 1 | 2012 | 140 | 0.090 |
Why?
| | Behavior, Addictive | 1 | 2013 | 88 | 0.090 |
Why?
| | Tetracyclines | 1 | 2012 | 17 | 0.090 |
Why?
| | Antigens | 3 | 2003 | 347 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 175 | 0.090 |
Why?
| | Tissue Distribution | 2 | 2016 | 327 | 0.090 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2012 | 87 | 0.090 |
Why?
| | Gene Transfer Techniques | 2 | 2010 | 185 | 0.090 |
Why?
| | Herpesvirus 4, Human | 1 | 2012 | 176 | 0.090 |
Why?
| | DNA Primers | 2 | 2010 | 511 | 0.090 |
Why?
| | Phenylurea Compounds | 1 | 1992 | 112 | 0.090 |
Why?
| | Mice, Inbred CBA | 1 | 2011 | 57 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2017 | 427 | 0.090 |
Why?
| | Macrophages, Peritoneal | 1 | 2011 | 89 | 0.090 |
Why?
| | Vasodilation | 1 | 2014 | 522 | 0.080 |
Why?
| | Sensation | 1 | 1991 | 55 | 0.080 |
Why?
| | Superoxides | 2 | 2022 | 204 | 0.080 |
Why?
| | Peptide Fragments | 3 | 2011 | 698 | 0.080 |
Why?
| | Stroke | 2 | 2018 | 1254 | 0.080 |
Why?
| | Rats, Inbred BN | 4 | 2012 | 55 | 0.080 |
Why?
| | Endocrine Glands | 1 | 1990 | 14 | 0.080 |
Why?
| | Heart Arrest | 1 | 2015 | 407 | 0.080 |
Why?
| | Phenylephrine | 1 | 1990 | 75 | 0.080 |
Why?
| | GABA Agonists | 4 | 2008 | 24 | 0.080 |
Why?
| | Benzylidene Compounds | 1 | 2010 | 20 | 0.080 |
Why?
| | Muscles | 1 | 1991 | 333 | 0.080 |
Why?
| | Prostaglandins | 2 | 2007 | 94 | 0.080 |
Why?
| | Drug Combinations | 2 | 2009 | 390 | 0.080 |
Why?
| | Food Preferences | 2 | 2008 | 126 | 0.080 |
Why?
| | Sphingolipids | 1 | 2010 | 83 | 0.080 |
Why?
| | Computational Biology | 2 | 2012 | 680 | 0.080 |
Why?
| | Protein Interaction Mapping | 1 | 2010 | 103 | 0.080 |
Why?
| | Receptor, Serotonin, 5-HT2C | 1 | 2009 | 14 | 0.080 |
Why?
| | Mitochondria | 1 | 2016 | 983 | 0.080 |
Why?
| | Anti-Infective Agents | 1 | 2012 | 242 | 0.080 |
Why?
| | Immunologic Factors | 1 | 2012 | 255 | 0.080 |
Why?
| | Receptors, Interleukin-1 Type I | 2 | 2011 | 25 | 0.080 |
Why?
| | Bradykinin | 1 | 2009 | 48 | 0.080 |
Why?
| | Stress Disorders, Traumatic | 1 | 2009 | 24 | 0.080 |
Why?
| | Hypnotics and Sedatives | 1 | 2012 | 214 | 0.080 |
Why?
| | Histamine | 1 | 2009 | 53 | 0.080 |
Why?
| | Dimethyl Sulfoxide | 1 | 2009 | 41 | 0.080 |
Why?
| | Afferent Pathways | 3 | 2005 | 46 | 0.080 |
Why?
| | Motor Neurons | 1 | 2012 | 234 | 0.080 |
Why?
| | Infusion Pumps | 1 | 2009 | 32 | 0.080 |
Why?
| | Eating | 3 | 2000 | 389 | 0.080 |
Why?
| | Amnesia, Retrograde | 2 | 2006 | 6 | 0.080 |
Why?
| | Injections, Intravenous | 3 | 1998 | 200 | 0.080 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2009 | 65 | 0.070 |
Why?
| | Toll-Like Receptor 9 | 1 | 2009 | 37 | 0.070 |
Why?
| | Lactams, Macrocyclic | 1 | 2009 | 51 | 0.070 |
Why?
| | Immunoglobulin M | 4 | 2001 | 284 | 0.070 |
Why?
| | Perception | 1 | 1992 | 377 | 0.070 |
Why?
| | Benzoquinones | 1 | 2009 | 47 | 0.070 |
Why?
| | Central Nervous System Infections | 1 | 2009 | 35 | 0.070 |
Why?
| | CpG Islands | 1 | 2009 | 165 | 0.070 |
Why?
| | Disease Susceptibility | 1 | 2011 | 346 | 0.070 |
Why?
| | Anxiety Disorders | 1 | 2012 | 368 | 0.070 |
Why?
| | Neoplasms | 2 | 2010 | 2870 | 0.070 |
Why?
| | Spatial Behavior | 1 | 2008 | 24 | 0.070 |
Why?
| | High-Throughput Screening Assays | 1 | 2010 | 174 | 0.070 |
Why?
| | Age Factors | 7 | 2010 | 3313 | 0.070 |
Why?
| | Cognition Disorders | 1 | 2012 | 537 | 0.070 |
Why?
| | RAW 264.7 Cells | 2 | 2019 | 50 | 0.070 |
Why?
| | Sex Factors | 2 | 2012 | 2096 | 0.070 |
Why?
| | Ligands | 1 | 2010 | 673 | 0.070 |
Why?
| | beta-Adrenergic Receptor Kinases | 1 | 2007 | 4 | 0.070 |
Why?
| | RNA, Antisense | 1 | 2007 | 18 | 0.060 |
Why?
| | Drugs, Investigational | 1 | 2007 | 31 | 0.060 |
Why?
| | Safety | 3 | 2008 | 355 | 0.060 |
Why?
| | Mice, Transgenic | 1 | 2012 | 2182 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2009 | 379 | 0.060 |
Why?
| | Cholesterol | 2 | 2003 | 399 | 0.060 |
Why?
| | Foreign-Body Reaction | 1 | 2007 | 36 | 0.060 |
Why?
| | Mental Disorders | 1 | 2016 | 1138 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 729 | 0.060 |
Why?
| | GABA-A Receptor Agonists | 3 | 2011 | 17 | 0.060 |
Why?
| | Receptors, Serotonin | 2 | 1997 | 35 | 0.060 |
Why?
| | Stereoisomerism | 2 | 2019 | 104 | 0.060 |
Why?
| | Mutation | 2 | 2015 | 4085 | 0.060 |
Why?
| | Enzyme Activation | 2 | 2005 | 765 | 0.060 |
Why?
| | Injections, Intramuscular | 1 | 2006 | 141 | 0.060 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 76 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2013 | 1339 | 0.060 |
Why?
| | Antibodies, Blocking | 1 | 2005 | 37 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 141 | 0.060 |
Why?
| | Centrifugation | 1 | 2005 | 27 | 0.060 |
Why?
| | Histocompatibility Antigens | 1 | 2006 | 102 | 0.060 |
Why?
| | Peptides | 2 | 2009 | 995 | 0.060 |
Why?
| | Transcriptome | 1 | 2012 | 1044 | 0.060 |
Why?
| | Electric Stimulation | 4 | 2011 | 276 | 0.060 |
Why?
| | Blotting, Western | 3 | 2013 | 1187 | 0.060 |
Why?
| | Cell Survival | 3 | 2019 | 1098 | 0.060 |
Why?
| | Caspase Inhibitors | 1 | 2005 | 81 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1379 | 0.060 |
Why?
| | Reinforcement Schedule | 3 | 2017 | 25 | 0.060 |
Why?
| | Complement C5a | 1 | 2005 | 54 | 0.060 |
Why?
| | Hormone Antagonists | 3 | 2016 | 34 | 0.050 |
Why?
| | Complement C3a | 1 | 2005 | 40 | 0.050 |
Why?
| | Adrenal Glands | 2 | 2018 | 77 | 0.050 |
Why?
| | Carbenoxolone | 1 | 2004 | 1 | 0.050 |
Why?
| | Glycyrrhizic Acid | 1 | 2004 | 3 | 0.050 |
Why?
| | Anti-Ulcer Agents | 1 | 2004 | 12 | 0.050 |
Why?
| | Postoperative Complications | 2 | 2012 | 2916 | 0.050 |
Why?
| | In Vitro Techniques | 1 | 2006 | 1047 | 0.050 |
Why?
| | Computer Simulation | 1 | 2009 | 1025 | 0.050 |
Why?
| | Nerve Compression Syndromes | 1 | 2004 | 22 | 0.050 |
Why?
| | Electric Countershock | 2 | 1984 | 126 | 0.050 |
Why?
| | Epilepsy | 1 | 2009 | 375 | 0.050 |
Why?
| | Stress, Mechanical | 1 | 2007 | 494 | 0.050 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2004 | 30 | 0.050 |
Why?
| | Cell Separation | 1 | 2005 | 307 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 1050 | 0.050 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2004 | 45 | 0.050 |
Why?
| | Catalase | 1 | 2004 | 130 | 0.050 |
Why?
| | Adenoviridae | 1 | 2005 | 199 | 0.050 |
Why?
| | N-Methylaspartate | 1 | 2004 | 43 | 0.050 |
Why?
| | Binding Sites | 2 | 2018 | 1327 | 0.050 |
Why?
| | Hypothermia | 1 | 2004 | 52 | 0.050 |
Why?
| | Peripheral Nervous System | 1 | 2003 | 20 | 0.050 |
Why?
| | Receptors, Opioid, kappa | 2 | 1994 | 9 | 0.050 |
Why?
| | Sample Size | 1 | 2004 | 123 | 0.050 |
Why?
| | Hydrocortisone | 5 | 2009 | 304 | 0.050 |
Why?
| | Complement Membrane Attack Complex | 1 | 2023 | 38 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2010 | 364 | 0.050 |
Why?
| | Viral Envelope Proteins | 1 | 2024 | 98 | 0.050 |
Why?
| | Mental Recall | 2 | 1995 | 222 | 0.050 |
Why?
| | Lymph Nodes | 3 | 2001 | 502 | 0.050 |
Why?
| | Aconitate Hydratase | 1 | 2003 | 14 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 4 | 2009 | 593 | 0.050 |
Why?
| | Pressure | 1 | 2004 | 225 | 0.050 |
Why?
| | Immunoglobulin G | 4 | 2002 | 893 | 0.050 |
Why?
| | Neck | 2 | 2001 | 108 | 0.050 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2002 | 18 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2005 | 375 | 0.050 |
Why?
| | Adult | 4 | 2022 | 40262 | 0.050 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2002 | 34 | 0.050 |
Why?
| | Immobility Response, Tonic | 2 | 2013 | 5 | 0.050 |
Why?
| | Peripheral Nerves | 1 | 2003 | 72 | 0.050 |
Why?
| | Reflex | 2 | 1994 | 69 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2004 | 377 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2004 | 301 | 0.050 |
Why?
| | Social Isolation | 1 | 2003 | 72 | 0.050 |
Why?
| | Peroxynitrous Acid | 1 | 2022 | 12 | 0.050 |
Why?
| | Antioxidants | 2 | 2022 | 549 | 0.050 |
Why?
| | Psychomotor Performance | 3 | 2015 | 328 | 0.050 |
Why?
| | Glycoproteins | 1 | 2024 | 355 | 0.050 |
Why?
| | NADPH Oxidase 2 | 1 | 2022 | 35 | 0.040 |
Why?
| | Death, Sudden | 1 | 1982 | 24 | 0.040 |
Why?
| | Lumbar Vertebrae | 1 | 2004 | 252 | 0.040 |
Why?
| | Nodose Ganglion | 2 | 1998 | 5 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2013 | 341 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 2 | 1995 | 415 | 0.040 |
Why?
| | Evoked Potentials, Auditory | 2 | 2011 | 180 | 0.040 |
Why?
| | Myelin Sheath | 1 | 2023 | 168 | 0.040 |
Why?
| | Ventricular Fibrillation | 1 | 1982 | 64 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2022 | 162 | 0.040 |
Why?
| | Stem Cells | 1 | 2006 | 625 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 292 | 0.040 |
Why?
| | Extracellular Vesicles | 1 | 2024 | 170 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2024 | 496 | 0.040 |
Why?
| | Interferon-gamma | 4 | 2001 | 784 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2024 | 3539 | 0.040 |
Why?
| | Viral Proteins | 1 | 2024 | 355 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2012 | 3403 | 0.040 |
Why?
| | Acute Disease | 2 | 2001 | 1028 | 0.040 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2022 | 95 | 0.040 |
Why?
| | Epinephrine | 3 | 2002 | 155 | 0.040 |
Why?
| | Protein Conformation | 2 | 2018 | 946 | 0.040 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2012 | 330 | 0.040 |
Why?
| | Injections | 2 | 2013 | 196 | 0.040 |
Why?
| | Phosphate-Binding Proteins | 1 | 2020 | 6 | 0.040 |
Why?
| | Organ Size | 1 | 2001 | 462 | 0.040 |
Why?
| | Aminopyridines | 2 | 2013 | 127 | 0.040 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 2011 | 39 | 0.040 |
Why?
| | Rodentia | 1 | 2020 | 61 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2016 | 2154 | 0.040 |
Why?
| | Crisis Intervention | 1 | 2020 | 37 | 0.040 |
Why?
| | Adjuvants, Immunologic | 2 | 2003 | 245 | 0.040 |
Why?
| | Depression | 2 | 2008 | 1533 | 0.040 |
Why?
| | Receptors, Mineralocorticoid | 1 | 1999 | 11 | 0.040 |
Why?
| | Peritoneum | 1 | 2000 | 45 | 0.040 |
Why?
| | Alzheimer Disease | 2 | 2020 | 619 | 0.040 |
Why?
| | Subarachnoid Space | 1 | 1999 | 8 | 0.040 |
Why?
| | Therapeutic Irrigation | 1 | 2000 | 69 | 0.040 |
Why?
| | Urocortins | 3 | 2004 | 24 | 0.040 |
Why?
| | Paresis | 1 | 1999 | 30 | 0.040 |
Why?
| | Motor Skills Disorders | 1 | 1999 | 25 | 0.040 |
Why?
| | Opioid Peptides | 1 | 1999 | 9 | 0.040 |
Why?
| | Coronary Disease | 1 | 1982 | 381 | 0.040 |
Why?
| | Fluorescent Dyes | 2 | 2012 | 329 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 1983 | 0.040 |
Why?
| | Pyrimidines | 2 | 2003 | 532 | 0.040 |
Why?
| | RNA, Double-Stranded | 1 | 2019 | 56 | 0.040 |
Why?
| | Immunity | 1 | 2000 | 139 | 0.040 |
Why?
| | alpha-MSH | 1 | 1998 | 6 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 173 | 0.040 |
Why?
| | Acute-Phase Reaction | 1 | 1998 | 37 | 0.040 |
Why?
| | Cerebellum | 1 | 2000 | 223 | 0.040 |
Why?
| | Glossopharyngeal Nerve | 1 | 1998 | 11 | 0.040 |
Why?
| | Anti-Bacterial Agents | 2 | 2008 | 1906 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2001 | 65 | 0.040 |
Why?
| | Optical Fibers | 1 | 2018 | 18 | 0.030 |
Why?
| | Limbic Lobe | 1 | 2018 | 3 | 0.030 |
Why?
| | Neuroanatomical Tract-Tracing Techniques | 1 | 2018 | 5 | 0.030 |
Why?
| | Protein Structure, Secondary | 1 | 2019 | 369 | 0.030 |
Why?
| | Stilbamidines | 1 | 2018 | 9 | 0.030 |
Why?
| | Injections, Epidural | 1 | 1998 | 28 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 1999 | 370 | 0.030 |
Why?
| | Vaccines, Inactivated | 1 | 2018 | 70 | 0.030 |
Why?
| | Memory, Short-Term | 1 | 2020 | 270 | 0.030 |
Why?
| | Bromodeoxyuridine | 2 | 2009 | 79 | 0.030 |
Why?
| | Administration, Intranasal | 1 | 2018 | 93 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2005 | 674 | 0.030 |
Why?
| | Cell Proliferation | 3 | 2012 | 2494 | 0.030 |
Why?
| | Isonicotinic Acids | 1 | 1997 | 2 | 0.030 |
Why?
| | Receptors, GABA | 1 | 1997 | 13 | 0.030 |
Why?
| | Thermosensing | 2 | 1997 | 12 | 0.030 |
Why?
| | Sucrose | 2 | 2008 | 112 | 0.030 |
Why?
| | Oxytocics | 1 | 1997 | 15 | 0.030 |
Why?
| | Amnesia, Anterograde | 2 | 2008 | 6 | 0.030 |
Why?
| | Immunoassay | 1 | 2018 | 109 | 0.030 |
Why?
| | Biguanides | 1 | 1997 | 10 | 0.030 |
Why?
| | Pyrroles | 1 | 1999 | 217 | 0.030 |
Why?
| | Mannose | 1 | 2017 | 23 | 0.030 |
Why?
| | Baclofen | 1 | 1997 | 21 | 0.030 |
Why?
| | Analgesia, Epidural | 1 | 1997 | 38 | 0.030 |
Why?
| | Skin Temperature | 2 | 1994 | 35 | 0.030 |
Why?
| | Histocytochemistry | 1 | 1997 | 79 | 0.030 |
Why?
| | Phosphopyruvate Hydratase | 2 | 2007 | 26 | 0.030 |
Why?
| | Basolateral Nuclear Complex | 1 | 2016 | 11 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 634 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 1999 | 382 | 0.030 |
Why?
| | Extracellular Space | 2 | 2009 | 120 | 0.030 |
Why?
| | Jurkat Cells | 1 | 2016 | 114 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 194 | 0.030 |
Why?
| | Nerve Net | 1 | 2000 | 285 | 0.030 |
Why?
| | Period Circadian Proteins | 1 | 2016 | 33 | 0.030 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1996 | 61 | 0.030 |
Why?
| | Immunoglobulins | 1 | 1996 | 160 | 0.030 |
Why?
| | Psychological Tests | 1 | 2016 | 131 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 1996 | 92 | 0.030 |
Why?
| | Dentate Gyrus | 2 | 2006 | 40 | 0.030 |
Why?
| | Anesthetics, Dissociative | 1 | 2016 | 46 | 0.030 |
Why?
| | Dysgammaglobulinemia | 1 | 1995 | 2 | 0.030 |
Why?
| | IgG Deficiency | 1 | 1995 | 6 | 0.030 |
Why?
| | Leukocytes | 2 | 2011 | 295 | 0.030 |
Why?
| | Optogenetics | 1 | 2016 | 109 | 0.030 |
Why?
| | Saccharin | 1 | 1995 | 8 | 0.030 |
Why?
| | Animal Diseases | 1 | 2015 | 8 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 1995 | 88 | 0.030 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1995 | 51 | 0.030 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 1 | 2014 | 10 | 0.030 |
Why?
| | Capsaicin | 1 | 2015 | 30 | 0.030 |
Why?
| | 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 1994 | 6 | 0.030 |
Why?
| | Chlorisondamine | 1 | 1994 | 3 | 0.030 |
Why?
| | Adrenal Medulla | 1 | 1994 | 9 | 0.030 |
Why?
| | Staphylococcal Infections | 1 | 1999 | 388 | 0.030 |
Why?
| | CD4 Antigens | 1 | 1995 | 139 | 0.030 |
Why?
| | Blood Proteins | 1 | 1997 | 249 | 0.030 |
Why?
| | Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2014 | 11 | 0.030 |
Why?
| | Monitoring, Physiologic | 2 | 1990 | 289 | 0.030 |
Why?
| | Substance P | 1 | 1994 | 39 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 2005 | 319 | 0.030 |
Why?
| | Weight Gain | 1 | 2018 | 556 | 0.030 |
Why?
| | Biphenyl Compounds | 1 | 1994 | 68 | 0.030 |
Why?
| | Ganglionectomy | 1 | 1994 | 2 | 0.030 |
Why?
| | Decerebrate State | 1 | 1994 | 3 | 0.030 |
Why?
| | Monocytes | 1 | 1997 | 538 | 0.030 |
Why?
| | Kupffer Cells | 1 | 1994 | 53 | 0.030 |
Why?
| | Ganglia, Sympathetic | 1 | 1994 | 14 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 329 | 0.030 |
Why?
| | Auditory Cortex | 1 | 1994 | 47 | 0.030 |
Why?
| | Valine | 1 | 2014 | 80 | 0.030 |
Why?
| | Basal Ganglia | 1 | 1994 | 57 | 0.030 |
Why?
| | Catalysis | 1 | 2014 | 322 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2016 | 242 | 0.030 |
Why?
| | Respiration | 1 | 2014 | 206 | 0.030 |
Why?
| | Adiposity | 1 | 2018 | 541 | 0.030 |
Why?
| | Biological Transport | 1 | 1995 | 412 | 0.020 |
Why?
| | Treatment Outcome | 3 | 2016 | 11643 | 0.020 |
Why?
| | Weight Loss | 2 | 2009 | 832 | 0.020 |
Why?
| | Pregnancy | 3 | 2017 | 7180 | 0.020 |
Why?
| | Infusion Pumps, Implantable | 1 | 2013 | 26 | 0.020 |
Why?
| | Receptors, Opioid, delta | 1 | 1992 | 10 | 0.020 |
Why?
| | Benzodiazepinones | 1 | 1992 | 18 | 0.020 |
Why?
| | Receptors, IgE | 1 | 2012 | 43 | 0.020 |
Why?
| | Anesthetics | 1 | 1993 | 99 | 0.020 |
Why?
| | Spodoptera | 1 | 2012 | 40 | 0.020 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2012 | 23 | 0.020 |
Why?
| | Receptors, IgG | 1 | 2012 | 76 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2012 | 49 | 0.020 |
Why?
| | Phosphatidylcholines | 1 | 2013 | 130 | 0.020 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2014 | 226 | 0.020 |
Why?
| | Gliosarcoma | 1 | 1992 | 8 | 0.020 |
Why?
| | Biological Assay | 1 | 2012 | 127 | 0.020 |
Why?
| | Lymphocyte Transfusion | 1 | 1992 | 20 | 0.020 |
Why?
| | Virus Activation | 1 | 2012 | 95 | 0.020 |
Why?
| | Biophysics | 1 | 2012 | 74 | 0.020 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2012 | 40 | 0.020 |
Why?
| | I-kappa B Proteins | 1 | 2012 | 74 | 0.020 |
Why?
| | Dimerization | 1 | 2012 | 193 | 0.020 |
Why?
| | Kinetics | 2 | 2006 | 1627 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 1084 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 128 | 0.020 |
Why?
| | Azoles | 1 | 2011 | 4 | 0.020 |
Why?
| | Nitrobenzenes | 1 | 2011 | 17 | 0.020 |
Why?
| | Tetrodotoxin | 1 | 2011 | 40 | 0.020 |
Why?
| | Foot | 1 | 1992 | 100 | 0.020 |
Why?
| | Physical Exertion | 1 | 1992 | 207 | 0.020 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2011 | 45 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2012 | 281 | 0.020 |
Why?
| | Molecular Mimicry | 1 | 2011 | 37 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2012 | 213 | 0.020 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2015 | 340 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2019 | 2048 | 0.020 |
Why?
| | Rotarod Performance Test | 1 | 2011 | 15 | 0.020 |
Why?
| | Biotin | 1 | 2011 | 32 | 0.020 |
Why?
| | Reflex, Righting | 1 | 2011 | 15 | 0.020 |
Why?
| | Pyramidal Tracts | 1 | 2011 | 30 | 0.020 |
Why?
| | Dextrans | 1 | 2011 | 86 | 0.020 |
Why?
| | Electrophysiology | 1 | 2011 | 218 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 2011 | 168 | 0.020 |
Why?
| | Arginine Vasopressin | 1 | 1990 | 44 | 0.020 |
Why?
| | Sphingosine | 1 | 2010 | 45 | 0.020 |
Why?
| | Interleukin-2 | 1 | 1992 | 437 | 0.020 |
Why?
| | Vasopressins | 1 | 1990 | 60 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 862 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 476 | 0.020 |
Why?
| | Lysophospholipids | 1 | 2010 | 77 | 0.020 |
Why?
| | Polyglycolic Acid | 1 | 2010 | 44 | 0.020 |
Why?
| | PC12 Cells | 1 | 2009 | 42 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 143 | 0.020 |
Why?
| | Dominance-Subordination | 1 | 2009 | 16 | 0.020 |
Why?
| | Serotonin Antagonists | 1 | 2009 | 30 | 0.020 |
Why?
| | Antimetabolites | 1 | 2009 | 21 | 0.020 |
Why?
| | Genes, fos | 1 | 2009 | 37 | 0.020 |
Why?
| | Vaccination | 1 | 2018 | 1422 | 0.020 |
Why?
| | Esters | 1 | 2009 | 78 | 0.020 |
Why?
| | Drinking | 2 | 1999 | 42 | 0.020 |
Why?
| | Temperature | 1 | 1992 | 678 | 0.020 |
Why?
| | Adaptation, Physiological | 2 | 2003 | 569 | 0.020 |
Why?
| | Myelin-Associated Glycoprotein | 1 | 2008 | 7 | 0.020 |
Why?
| | Aldehydes | 1 | 2009 | 142 | 0.020 |
Why?
| | Electromyography | 1 | 1991 | 415 | 0.020 |
Why?
| | Biological Products | 1 | 2012 | 251 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2009 | 321 | 0.020 |
Why?
| | Myelin Proteins | 1 | 2008 | 45 | 0.020 |
Why?
| | Particle Size | 1 | 2010 | 406 | 0.020 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2008 | 19 | 0.020 |
Why?
| | Lactic Acid | 1 | 2010 | 302 | 0.020 |
Why?
| | Exercise Test | 1 | 2011 | 634 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1995 | 1128 | 0.020 |
Why?
| | Parietal Lobe | 1 | 2008 | 60 | 0.020 |
Why?
| | Action Potentials | 1 | 2011 | 506 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1992 | 337 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 1995 | 963 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2011 | 824 | 0.020 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2009 | 139 | 0.020 |
Why?
| | Naproxen | 1 | 2007 | 21 | 0.020 |
Why?
| | Bronchodilator Agents | 1 | 2008 | 182 | 0.020 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2007 | 9 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2009 | 366 | 0.020 |
Why?
| | Endotoxemia | 1 | 2007 | 87 | 0.020 |
Why?
| | Anticonvulsants | 1 | 2009 | 234 | 0.020 |
Why?
| | Mesentery | 2 | 1998 | 45 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2929 | 0.020 |
Why?
| | Gyrus Cinguli | 1 | 2006 | 96 | 0.020 |
Why?
| | Heart Rate | 1 | 1990 | 849 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2009 | 744 | 0.020 |
Why?
| | Thiocarbamates | 1 | 2005 | 6 | 0.010 |
Why?
| | Microtubule-Associated Proteins | 1 | 2007 | 196 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2012 | 954 | 0.010 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 49 | 0.010 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2005 | 71 | 0.010 |
Why?
| | Phenotype | 2 | 2009 | 3157 | 0.010 |
Why?
| | Locus Coeruleus | 1 | 2005 | 24 | 0.010 |
Why?
| | Estrous Cycle | 1 | 2005 | 23 | 0.010 |
Why?
| | 5,7-Dihydroxytryptamine | 1 | 2004 | 2 | 0.010 |
Why?
| | Pro-Opiomelanocortin | 1 | 2004 | 20 | 0.010 |
Why?
| | Aminoglutethimide | 1 | 2004 | 5 | 0.010 |
Why?
| | Metyrapone | 1 | 2004 | 5 | 0.010 |
Why?
| | Proline | 1 | 2005 | 83 | 0.010 |
Why?
| | Serotonin Agents | 1 | 2004 | 8 | 0.010 |
Why?
| | Motor Cortex | 1 | 2005 | 65 | 0.010 |
Why?
| | Rats, Mutant Strains | 1 | 2004 | 20 | 0.010 |
Why?
| | Reptilian Proteins | 1 | 2004 | 3 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2009 | 780 | 0.010 |
Why?
| | Group II Phospholipases A2 | 1 | 2004 | 10 | 0.010 |
Why?
| | Receptors, Leptin | 1 | 2004 | 25 | 0.010 |
Why?
| | Electrochemistry | 1 | 2004 | 73 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2004 | 81 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1739 | 0.010 |
Why?
| | Catecholamines | 1 | 2004 | 87 | 0.010 |
Why?
| | Concanavalin A | 1 | 2003 | 71 | 0.010 |
Why?
| | HIV Infections | 1 | 1999 | 3079 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2430 | 0.010 |
Why?
| | Serotonin 5-HT1 Receptor Antagonists | 1 | 2003 | 2 | 0.010 |
Why?
| | Cholesterol, VLDL | 1 | 2003 | 5 | 0.010 |
Why?
| | Electrolysis | 1 | 2003 | 2 | 0.010 |
Why?
| | Immobilization | 1 | 2003 | 53 | 0.010 |
Why?
| | Sepsis | 1 | 2010 | 640 | 0.010 |
Why?
| | Blood Pressure | 1 | 1990 | 1759 | 0.010 |
Why?
| | Nanoparticles | 1 | 2010 | 519 | 0.010 |
Why?
| | Sleep | 1 | 2011 | 901 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 2143 | 0.010 |
Why?
| | Oxathiins | 1 | 2002 | 1 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 2003 | 194 | 0.010 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2004 | 192 | 0.010 |
Why?
| | Drug Resistance | 1 | 2003 | 153 | 0.010 |
Why?
| | Prostheses and Implants | 1 | 1984 | 141 | 0.010 |
Why?
| | Physical Examination | 1 | 2003 | 236 | 0.010 |
Why?
| | Brain Neoplasms | 1 | 1992 | 1318 | 0.010 |
Why?
| | Aniline Compounds | 1 | 2003 | 119 | 0.010 |
Why?
| | Cell Division | 1 | 2003 | 766 | 0.010 |
Why?
| | Wallerian Degeneration | 1 | 2001 | 3 | 0.010 |
Why?
| | Gelatin Sponge, Absorbable | 1 | 2001 | 5 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2006 | 1129 | 0.010 |
Why?
| | Tachycardia | 1 | 1982 | 57 | 0.010 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2002 | 58 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 2003 | 353 | 0.010 |
Why?
| | Epitopes | 1 | 2003 | 485 | 0.010 |
Why?
| | Muscle Denervation | 1 | 2001 | 8 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 2001 | 164 | 0.010 |
Why?
| | Emotions | 1 | 2006 | 577 | 0.010 |
Why?
| | Immunoglobulin Isotypes | 1 | 2001 | 35 | 0.010 |
Why?
| | Luminescent Measurements | 1 | 2001 | 76 | 0.010 |
Why?
| | Organ Specificity | 1 | 2002 | 312 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2004 | 338 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2006 | 905 | 0.010 |
Why?
| | Spironolactone | 1 | 2001 | 39 | 0.010 |
Why?
| | Hypertrophy | 1 | 2001 | 127 | 0.010 |
Why?
| | Long-Term Potentiation | 1 | 2002 | 200 | 0.010 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2005 | 422 | 0.010 |
Why?
| | Thymus Gland | 1 | 2001 | 311 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2006 | 1782 | 0.010 |
Why?
| | Periaqueductal Gray | 1 | 1999 | 37 | 0.010 |
Why?
| | Peritoneal Cavity | 1 | 1998 | 30 | 0.010 |
Why?
| | Prognosis | 1 | 2007 | 4278 | 0.010 |
Why?
| | Administration, Oral | 1 | 2001 | 847 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 1998 | 125 | 0.010 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1998 | 24 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 274 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2007 | 5389 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2001 | 1172 | 0.010 |
Why?
| | Butoxamine | 1 | 1996 | 1 | 0.010 |
Why?
| | Atenolol | 1 | 1996 | 7 | 0.010 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 1996 | 23 | 0.010 |
Why?
| | Propranolol | 1 | 1996 | 44 | 0.010 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 1996 | 35 | 0.010 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1996 | 158 | 0.010 |
Why?
| | Diazepam | 1 | 1995 | 33 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1999 | 478 | 0.010 |
Why?
| | Anti-Anxiety Agents | 1 | 1995 | 45 | 0.010 |
Why?
| | Adrenergic beta-Antagonists | 1 | 1996 | 250 | 0.010 |
Why?
| | Electrodes, Implanted | 1 | 1995 | 115 | 0.010 |
Why?
| | Cytological Techniques | 1 | 1995 | 28 | 0.010 |
Why?
| | Nylons | 1 | 1995 | 23 | 0.010 |
Why?
| | Jugular Veins | 1 | 1994 | 42 | 0.010 |
Why?
| | Prospective Studies | 1 | 2007 | 7970 | 0.010 |
Why?
| | Horseradish Peroxidase | 1 | 1994 | 26 | 0.010 |
Why?
| | Methoxyflurane | 1 | 1993 | 2 | 0.010 |
Why?
| | Chloral Hydrate | 1 | 1993 | 3 | 0.010 |
Why?
| | Halothane | 1 | 1993 | 8 | 0.010 |
Why?
| | Pentobarbital | 1 | 1993 | 17 | 0.010 |
Why?
| | Xylazine | 1 | 1993 | 15 | 0.010 |
Why?
| | CD4-CD8 Ratio | 1 | 1992 | 23 | 0.010 |
Why?
| | Cholesterol, Dietary | 1 | 1992 | 15 | 0.010 |
Why?
| | Cold Temperature | 1 | 1993 | 207 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1992 | 251 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 1995 | 1126 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1992 | 177 | 0.010 |
Why?
| | Obesity | 1 | 2004 | 3057 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1992 | 919 | 0.000 |
Why?
| | Dietary Fats | 1 | 1992 | 313 | 0.000 |
Why?
| | Actuarial Analysis | 1 | 1984 | 21 | 0.000 |
Why?
| | Adolescent | 1 | 1982 | 22281 | 0.000 |
Why?
| | Aged | 1 | 1982 | 25850 | 0.000 |
Why?
| | Recurrence | 1 | 1984 | 1134 | 0.000 |
Why?
| | Electrocardiography | 1 | 1984 | 660 | 0.000 |
Why?
| | Middle Aged | 1 | 1982 | 35762 | 0.000 |
Why?
|
|
Watkins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|